晚期肾细胞癌（RCC）的治疗管理：拉丁美洲肿瘤协作组（LACOG）和拉丁美洲肾癌协作组（LARCG）的专家小组建议。
Advanced renal cell carcinoma (RCC) management: an expert panel recommendation from the Latin American Cooperative Oncology Group (LACOG) and the Latin American Renal Cancer Group (LARCG).
机构信息
Hospital Israelita Albert Einstein, Av. Albert Einstein, 627-Morumbi, São Paulo, SP, 05652-900, Brazil.
Centro Paulista de Oncologia/Oncoclínicas, Av. Brigadeiro Faria Lima, 4300-Vila Olímpia, São Paulo, SP, 01452-000, Brazil.
出版信息
J Cancer Res Clin Oncol. 2020 Jul;146(7):1829-1845. doi: 10.1007/s00432-020-03236-4. Epub 2020 May 14.
Abstract
PURPOSE
The outcome of RCC has improved considerably in the last few years, and the treatment options have increased. LACOG-GU and LARCG held a consensus meeting to develop guidelines to support the clinical decisions of physicians and other health professionals involved in the care of RCC patients.
METHODS
Eighty questions addressing relevant advanced RCC treatments were previously formulated by a panel of experts. The voting panel comprised 26 specialists from the LACOG-GU/LARCG. Consensus was determined as 75% agreement. For questions with less than 75% agreement, a new discussion was held, and consensus was determined by the majority of votes after the second voting session.
RESULTS
The recommendations were based on the highest level of scientific evidence or by the opinion of the RCC experts when no relevant research data were available.
CONCLUSION
This manuscript provides guidance for advanced RCC treatment according to the LACOG-GU/LARCG expert recommendations.
摘要
目的
近年来，RCC 的治疗效果有了显著提高，治疗选择也有所增加。LACOG-GU 和 LARCG 举行了一次共识会议，制定了指南，以支持参与 RCC 患者治疗的医生和其他卫生专业人员的临床决策。
方法
一个专家组预先制定了 80 个关于相关晚期 RCC 治疗的问题。投票小组成员由来自 LACOG-GU/LARCG 的 26 名专家组成。75%的一致意见确定为共识。对于未达成 75%一致意见的问题，将进行新的讨论，并在第二次投票会议后，以多数票确定共识。
结果
这些建议是基于最高水平的科学证据，或在没有相关研究数据的情况下，根据 RCC 专家的意见得出的。
结论
本文根据 LACOG-GU/LARCG 专家建议，为晚期 RCC 治疗提供了指导。
相似文献
1
Advanced renal cell carcinoma (RCC) management: an expert panel recommendation from the Latin American Cooperative Oncology Group (LACOG) and the Latin American Renal Cancer Group (LARCG).晚期肾细胞癌（RCC）的治疗管理：拉丁美洲肿瘤协作组（LACOG）和拉丁美洲肾癌协作组（LARCG）的专家小组建议。
J Cancer Res Clin Oncol. 2020 Jul;146(7):1829-1845. doi: 10.1007/s00432-020-03236-4. Epub 2020 May 14.
2
Renal cell cancer treatment: an expert panel recommendation from the Latin American cooperative group-genitourinary and the Latin American renal cancer group: focus on surgery.肾细胞癌治疗：来自拉丁美洲泌尿生殖系统合作组和拉丁美洲肾癌组的专家小组建议：聚焦手术治疗
Ther Adv Urol. 2019 Sep 9;11:1756287219872324. doi: 10.1177/1756287219872324. eCollection 2019 Jan-Dec.
3
Immunotherapy for advanced renal cell cancer.晚期肾细胞癌的免疫疗法。
Cochrane Database Syst Rev. 2005 Jan 25(1):CD001425. doi: 10.1002/14651858.CD001425.pub2.
4
Comparison of Two Modern Survival Prediction Tools, SORG-MLA and METSSS, in Patients With Symptomatic Long-bone Metastases Who Underwent Local Treatment With Surgery Followed by Radiotherapy and With Radiotherapy Alone.两种现代生存预测工具 SORG-MLA 和 METSSS 在接受手术联合放疗和单纯放疗治疗有症状长骨转移患者中的比较。
Clin Orthop Relat Res. 2024 Dec 1;482(12):2193-2208. doi: 10.1097/CORR.0000000000003185. Epub 2024 Jul 23.
5
EAU guidelines on renal cell carcinoma: 2014 update.EAU 指南：肾细胞癌. 2014 年更新版.
Eur Urol. 2015 May;67(5):913-24. doi: 10.1016/j.eururo.2015.01.005. Epub 2015 Jan 21.
6
Cytoreductive nephrectomy in metastatic renal cell carcinoma.细胞减灭性肾切除术治疗转移性肾细胞癌。
Cochrane Database Syst Rev. 2024 Jun 7;6(6):CD013773. doi: 10.1002/14651858.CD013773.pub2.
7
Systematic review of perioperative and quality-of-life outcomes following surgical management of localised renal cancer.手术治疗局限性肾癌的围手术期和生活质量结局的系统评价。
Eur Urol. 2012 Dec;62(6):1097-117. doi: 10.1016/j.eururo.2012.07.028. Epub 2012 Jul 20.
8
Hail Lifestyle Medicine consensus position statement as a medical specialty: Middle Eastern perspective.欢呼将生活方式医学作为一门医学专业的共识立场声明：中东视角。
Front Public Health. 2025 Jun 20;13:1455871. doi: 10.3389/fpubh.2025.1455871. eCollection 2025.
9
First-line therapy for adults with advanced renal cell carcinoma: a systematic review and network meta-analysis.一线治疗成人晚期肾细胞癌：系统评价和网络荟萃分析。
Cochrane Database Syst Rev. 2023 May 4;5(5):CD013798. doi: 10.1002/14651858.CD013798.pub2.
10
European Association of Urology Guidelines on Renal Cell Carcinoma: The 2025 Update.欧洲泌尿外科学会肾细胞癌指南：2025年更新版
Eur Urol. 2025 Jun;87(6):683-696. doi: 10.1016/j.eururo.2025.02.020. Epub 2025 Mar 20.
引用本文的文献
1
Renal cell cancer treatment: the Latin American Cooperative Oncology Group (LACOG) and the Latin American Renal Cancer Group (LARCG) surgery-focused consensus update.肾细胞癌治疗：拉丁美洲肿瘤协作组（LACOG）和拉丁美洲肾癌组（LARCG）以手术为重点的共识更新
Ther Adv Urol. 2025 Apr 14;17:17562872241312581. doi: 10.1177/17562872241312581. eCollection 2025 Jan-Dec.
2
Synergistic effects of 6-shogaol and hyperthermia on ACHN renal cancer cells: modulation of ROS and heat shock pro-teins in cancer therapy.6-姜辣素与热疗对ACHN肾癌细胞的协同作用：癌症治疗中活性氧和热休克蛋白的调节
Front Pharmacol. 2025 Feb 20;16:1522285. doi: 10.3389/fphar.2025.1522285. eCollection 2025.
3
Ailanthone suppresses cell proliferation of renal cell carcinoma partially via inhibition of EZH2.臭椿酮通过部分抑制EZH2来抑制肾细胞癌的细胞增殖。
Discov Oncol. 2024 Sep 19;15(1):464. doi: 10.1007/s12672-024-01347-9.
4
Focal therapy for oligometastatic and oligoprogressive renal cell carcinoma: a narrative review.寡转移和寡进展性肾细胞癌的局部治疗：叙述性综述。
Future Oncol. 2024;20(33):2573-2588. doi: 10.1080/14796694.2024.2389769. Epub 2024 Sep 11.
5
Advanced renal cell carcinoma management: the Latin American Cooperative Oncology Group (LACOG) and the Latin American Renal Cancer Group (LARCG) consensus update.晚期肾细胞癌的治疗管理：拉丁美洲肿瘤协作组（LACOG）和拉丁美洲肾癌协作组（LARCG）的共识更新。
J Cancer Res Clin Oncol. 2024 Apr 9;150(4):183. doi: 10.1007/s00432-024-05663-z.
6
Unveiling the therapeutic potential of cabozantinib-loaded poly D,L-lactic-co-glycolic acid and polysarcosine nanoparticles in inducing apoptosis and cytotoxicity in human HepG2 hepatocellular carcinoma cell lines and anti-tumor activity in SCID female mice.揭示载有卡博替尼的聚D，L-乳酸-乙醇酸共聚物和聚肌氨酸纳米颗粒在诱导人肝癌HepG2细胞系凋亡和细胞毒性以及在SCID雌性小鼠体内的抗肿瘤活性方面的治疗潜力。
Front Oncol. 2023 Feb 15;13:1125857. doi: 10.3389/fonc.2023.1125857. eCollection 2023.
7
Update on the treatment of metastatic renal cell carcinoma.转移性肾细胞癌的治疗进展
World J Clin Oncol. 2022 Jan 24;13(1):1-8. doi: 10.5306/wjco.v13.i1.1.
8
Balancing the Risk-Benefit Ratio of Immune Checkpoint Inhibitor and Anti-VEGF Combination Therapy in Renal Cell Carcinoma: A Systematic Review and Meta-Analysis.肾细胞癌中免疫检查点抑制剂与抗血管内皮生长因子联合治疗的风险效益比平衡：一项系统评价和荟萃分析
Front Oncol. 2021 Oct 14;11:739263. doi: 10.3389/fonc.2021.739263. eCollection 2021.
本文引用的文献
1
Phase II Study Investigating the Safety and Efficacy of Savolitinib and Durvalumab in Metastatic Papillary Renal Cancer (CALYPSO).Ⅱ期研究调查索凡替尼联合度伐利尤单抗治疗转移性乳头状肾细胞癌（CALYPSO）的安全性和疗效。
J Clin Oncol. 2023 May 10;41(14):2493-2502. doi: 10.1200/JCO.22.01414. Epub 2023 Feb 21.
2
Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study.替沃扎尼布与索拉非尼治疗晚期肾细胞癌患者（TIVO-3）：一项多中心、随机、对照、开放标签的 3 期研究。
Lancet Oncol. 2020 Jan;21(1):95-104. doi: 10.1016/S1470-2045(19)30735-1. Epub 2019 Dec 3.
3
Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial.纳武利尤单抗联合伊匹单抗对比舒尼替尼用于晚期肾细胞癌的一线治疗：来自一项随机、对照、III 期临床试验的疗效和安全性结果的扩展随访。
Lancet Oncol. 2019 Oct;20(10):1370-1385. doi: 10.1016/S1470-2045(19)30413-9. Epub 2019 Aug 16.
4
The role of metastasectomy in advanced renal cell carcinoma.转移性肾细胞癌切除术的作用。
Expert Rev Anticancer Ther. 2019 Jul;19(7):603-611. doi: 10.1080/14737140.2019.1625772. Epub 2019 Jun 8.
5
Surgical Metastasectomy in Renal Cell Carcinoma: A Systematic Review.肾细胞癌的外科转移切除术：系统评价。
Eur Urol Oncol. 2019 Mar;2(2):141-149. doi: 10.1016/j.euo.2018.08.028. Epub 2018 Sep 24.
6
Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†.肾细胞癌：ESMO 诊断、治疗及随访临床实践指南†
Ann Oncol. 2019 May 1;30(5):706-720. doi: 10.1093/annonc/mdz056.
7
Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.阿维鲁单抗联合阿昔替尼与舒尼替尼治疗晚期肾细胞癌。
N Engl J Med. 2019 Mar 21;380(12):1103-1115. doi: 10.1056/NEJMoa1816047. Epub 2019 Feb 16.
8
irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial.irRECIST 用于评估纳武利尤单抗治疗转移性透明细胞肾细胞癌候选生物标志物反应：一项 II 期前瞻性临床试验分析。
Clin Cancer Res. 2019 Apr 1;25(7):2174-2184. doi: 10.1158/1078-0432.CCR-18-3206. Epub 2019 Jan 22.
9
Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma.纳武利尤单抗联合伊匹单抗治疗失败后的转移性肾细胞癌二线靶向治疗。
Eur J Cancer. 2019 Feb;108:33-40. doi: 10.1016/j.ejca.2018.11.031. Epub 2019 Jan 5.
10
Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical Trial.舒尼替尼治疗同步转移性肾细胞癌患者中即刻与延迟细胞减瘤性肾切除术的比较：SURTIME 随机临床试验。
JAMA Oncol. 2019 Feb 1;5(2):164-170. doi: 10.1001/jamaoncol.2018.5543.
Zotero 插件